AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36074799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligonol
Number of subjects: 40
Study 36074799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32303884 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam induction at 6 mg kg-1 h-1 (group A)
Number of subjects: 67
Study 32303884 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam induction at 12 mg kg-1 h-1 (group B)
Number of subjects: 67
Study 32303884 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam maintenance infusion up to 2 mg kg-1 h-1 for both groups
Number of subjects: 67
Study 35104848 — intervention group
Group type: EXPERIMENTAL
Intervention: Omilancor 440 mg QD
Number of subjects: 198
Study 35104848 — intervention group
Group type: EXPERIMENTAL
Intervention: Omilancor 880 mg QD
Number of subjects: 198
Study 35104848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 33050924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 mg, 2 tablets BID on day 0, 2 tablets QD from day 1 to 9
Number of subjects: 1057
Study 33050924 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg, 1 tablet QD from day 0 to 9
Number of subjects: 1057
Study 33050924 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir 200 mg, 12 tablets BID on day 0, 6 tablets BID from day 1 to 9
Number of subjects: 1057
Study 33050924 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 20 mg, 1 tablet QD from day 0 to 9
Number of subjects: 1057
Study 33050924 — intervention group
Group type: COMPARATOR
Intervention: Complex of vitamins and trace elements (AZINC Forme et Vitalité®), 1 capsule BID for 10 days
Number of subjects: 1057
Study 32042407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod protein hydrolysate (CPH) 10 mg/kg BW
Number of subjects: 31
Study 32042407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod protein hydrolysate (CPH) 40 mg/kg BW
Number of subjects: 31
Study 32838661 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 760
Study 32838661 — intervention group
Group type: COMPARATOR
Intervention: Control (hydration therapy)
Number of subjects: 760
Study 35236256 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Heel Wedge (IHW)
Number of subjects: 42
Study 35236256 — intervention group
Group type: EXPERIMENTAL
Intervention: External Heel Wedge (EHW)
Number of subjects: 42
Study 35236256 — intervention group
Group type: COMPARATOR
Intervention: Control group (no podalic stimulation)
Number of subjects: 42
Study 34036689 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-cognitive-behavioral therapy (CBT)
Number of subjects: 70
Study 34036689 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 70
Study 35390490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitality Acupunch (VA) exercise, 3 times a week, 40 min each session for 24 weeks
Number of subjects: 81
Study 35390490 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular activities of daily living)
Number of subjects: 81
Study 34061380 — intervention group
Group type: EXPERIMENTAL
Intervention: U-NetAC
Number of subjects: 236
Study 34061380 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoencoderAC
Number of subjects: 236
Study 34061380 — intervention group
Group type: COMPARATOR
Intervention: ChangAC
Number of subjects: 236
Study 34061380 — intervention group
Group type: EXPERIMENTAL
Intervention: CTAC
Number of subjects: 236
Study 36162986 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy-supportive communication style
Number of subjects: 1918
Study 36162986 — intervention group
Group type: COMPARATOR
Intervention: Controlling communication style
Number of subjects: 1918
Study 36162986 — intervention group
Group type: COMPARATOR
Intervention: External motivators (monetary voucher or corona pass)
Number of subjects: 1918
Study 33692297 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 14
Study 33692297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 32897035 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous molgramostim (300 μg once daily by inhalation)
Number of subjects: 138
Study 32897035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 35634513 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐7 M melatonin added to the culture medium; n=48
Number of subjects: 42
Study 35634513 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐7 M melatonin added to the culture medium; n=71
Number of subjects: 42
Study 35634513 — intervention group
Group type: COMPARATOR
Intervention: Control group; n=72
Number of subjects: 42
Study 34786350 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM plus Check Your Drinking (M + CYD)
Number of subjects: 986
Study 34786350 — intervention group
Group type: COMPARATOR
Intervention: MoodGYM (M-only)
Number of subjects: 986
Study 32617805 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning Slit Topography (SST)
Number of subjects: 95
Study 32617805 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared Pachymetry (IRP)
Number of subjects: 95
Study 32617805 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound Pachymetry (USP)
Number of subjects: 95
Study 34469338 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mm cylindrical light guide
Number of subjects: 85
Study 34469338 — intervention group
Group type: COMPARATOR
Intervention: 8 × 15-mm cylindrical light guide
Number of subjects: 85
Study 34469338 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (6-mm and 8 × 15-mm light guides)
Number of subjects: 85
Study 34085873 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment and feedback combined with vaccine communication training and behavioral nudges (vaccine commitment posters)
Number of subjects: 215
Study 34085873 — intervention group
Group type: COMPARATOR
Intervention: Assessment and feedback
Number of subjects: 215
Study 34085873 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention groups (assessment and feedback with communication training and behavioral nudges, and assessment and feedback alone)
Number of subjects: 215
Study 34085873 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of HPV vaccine-hesitant children
Number of subjects: 215
Study 33333513 — intervention group
Group type: EXPERIMENTAL
Intervention: Mansoura Fiberoptic Endoscopic Evaluation of Swallowing Residue Rating Scale (MFRRS)
Number of subjects: 30
Study 35237860 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon angioplasty (DCBA)
Number of subjects: 138
Study 35237860 — intervention group
Group type: COMPARATOR
Intervention: Conventional percutaneous transluminal angioplasty (PTA)
Number of subjects: 138
Study 32529903 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal orientation
Number of subjects: 100
Study 32529903 — intervention group
Group type: COMPARATOR
Intervention: Transverse orientation
Number of subjects: 100
Study 35295236 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesogaberan 120 mg modified release twice daily
Number of subjects: 22
Study 35295236 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 22
Study 32339978 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy
Number of subjects: 720
Study 34209581 — intervention group
Group type: EXPERIMENTAL
Intervention: Stim
Number of subjects: 89
Study 34209581 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 89
Study 35928056 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg) on days one and two, followed by misoprostol (200 or 400 μg, vaginally, six-hourly, up to three doses in 12 h)
Number of subjects: 200
Study 35928056 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone (one dose on day one) followed by misoprostol on day three (historical control)
Number of subjects: 200
Study 35928056 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg) on days one and two, followed by misoprostol
Number of subjects: 200
Study 35797219 — intervention group
Group type: COMPARATOR
Intervention: Additional anthracycline-containing chemotherapy
Number of subjects: 336
Study 34039277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application for monitoring patients under home oxygen therapy
Number of subjects: 0
Study 34039277 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow‐up methods (periodic visits of a respiratory therapist)
Number of subjects: 0
Study 35938620 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music of their own choice during the procedure
Number of subjects: 93
Study 35938620 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 93
Study 35217351 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA cathodal high-definition tDCS targeting the seizure-onset zone for 30 minutes for 2 weeks (10 sessions total).
Number of subjects: 20
Study 35217351 — intervention group
Group type: COMPARATOR
Intervention: Cathodal high-definition tDCS (treatment group)
Number of subjects: 20
Study 32912305 — intervention group
Group type: EXPERIMENTAL
Intervention: CareHand app
Number of subjects: 58
Study 32912305 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 58
Study 35215057 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges (two per day for 90 days) with regular oral hygiene
Number of subjects: 116
Study 35215057 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges (two per day for 90 days) with regular oral hygiene
Number of subjects: 116
Study 34533249 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and ALES (artichoke leaf extract)
Number of subjects: 0
Study 34533249 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E and ALES (artichoke leaf extract)
Number of subjects: 0
Study 34533249 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and Vitamin E
Number of subjects: 0
Study 33375899 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion-Focused Therapy (CFT) - 8 sessions
Number of subjects: 42
Study 33375899 — intervention group
Group type: COMPARATOR
Intervention: Control group - no therapy
Number of subjects: 42
Study 33091587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving EHR-based best practice alert and psychiatrist review of prescriptions.
Number of subjects: 800
Study 33091587 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 800
Study 35033158 — intervention group
Group type: EXPERIMENTAL
Intervention: Average blood glucose level
Number of subjects: 182
Study 32239365 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery-oriented cognitive behavioural workshop
Number of subjects: 0
Study 32239365 — intervention group
Group type: EXPERIMENTAL
Intervention: Online booster session
Number of subjects: 0
Study 32239365 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of illness and older age
Number of subjects: 0
Study 36272846 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 159
Study 36272846 — intervention group
Group type: COMPARATOR
Intervention: Sham Reiki
Number of subjects: 159
Study 36272846 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 159
Study 33460300 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual dissection manual (n = 96)
Number of subjects: 279
Study 33460300 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved written manual (n = 94)
Number of subjects: 279
Study 33460300 — intervention group
Group type: COMPARATOR
Intervention: Standard dissection manual (Control group, n = 89)
Number of subjects: 279
Study 34766664 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred clinical prediction tool and e-health platform
Number of subjects: 14
Study 34766664 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 14
Study 34762057 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile diary app
Number of subjects: 78
Study 34762057 — intervention group
Group type: COMPARATOR
Intervention: Paper-based diary cards
Number of subjects: 78
Study 33149136 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis at the start of anti‐myeloma treatment
Number of subjects: 838
Study 33149136 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 838
Study 33149136 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloma patients
Number of subjects: 838
Study 616553345 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil 0.5%/Salicylic Acid 10%
Number of subjects: 0
Study 616553345 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 34529869 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of transobturator tape sling (TOT) and low-dose Abobotulinumtoxin-A injection (300 U injected in 20–30 sites)
Number of subjects: 60
Study 34529869 — intervention group
Group type: COMPARATOR
Intervention: TOT surgery alone
Number of subjects: 60
Study 34529869 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Part 2)
Number of subjects: 60
Study 34529869 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 60
Study 32396266 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP4V2 H331P variant
Number of subjects: 60
Study 32396266 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP4V2 G410C variant
Number of subjects: 60
Study 32396266 — intervention group
Group type: COMPARATOR
Intervention: Wild-type CYP4V2
Number of subjects: 60
Study 32396266 — intervention group
Group type: EXPERIMENTAL
Intervention: Other four CYP4V2 amino variants
Number of subjects: 60
Study 33632930 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin at 75 mg/m2 for eight cycles
Number of subjects: 504
Study 33632930 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin at 75 mg/m2 for eight cycles with dexrazoxane coadministration
Number of subjects: 504
Study 35882292 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD supplement (Hemp Extract, 150 mg)
Number of subjects: 20
Study 35882292 — intervention group
Group type: COMPARATOR
Intervention: Control (supplement pellets without CBD)
Number of subjects: 20
Study 33408145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK) 0.25 mg/kg or 0.40 mg/kg
Number of subjects: 110
Study 33408145 — intervention group
Group type: COMPARATOR
Intervention: Alteplase 0.9 mg/kg
Number of subjects: 110
Study 33408145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK)
Number of subjects: 110
Study 33408145 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 110
Study 32664094 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phenylephrine infusion (0.5 μg/kg/min) for 5 minutes before BCP
Number of subjects: 66
Study 32664094 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phenylephrine infusion (1.0 μg/kg/min) for 5 minutes before BCP
Number of subjects: 66
Study 32664094 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline (control group)
Number of subjects: 66
Study 34261364 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 19
Study 34261364 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (0.3 mg/kg IV)
Number of subjects: 19
Study 34261364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 33350782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tong-Xie-An-Chang Decoction (TXACD)
Number of subjects: 72
Study 33350782 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium bromide tablets placebo
Number of subjects: 72
Study 33350782 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium bromide tablets
Number of subjects: 72
Study 36174595 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (3-day course of twice-daily dosing followed by weekly dosing for 4 weeks)
Number of subjects: 1480
Study 36174595 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin (no antimalarial activity)
Number of subjects: 1480
Study 36174595 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 1480
Study 36174595 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin
Number of subjects: 1480
Study 36112940 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperSpeed Golf™ weighted-club warm-up
Number of subjects: 12
Study 36112940 — intervention group
Group type: COMPARATOR
Intervention: Control warm-up
Number of subjects: 12
Study 32316994 — intervention group
Group type: EXPERIMENTAL
Intervention: Different methods of applying KDIGO criteria for AKI
Number of subjects: 1010
Study 32316994 — intervention group
Group type: EXPERIMENTAL
Intervention: Different methods of estimating missing baseline serum creatinine (sCr)
Number of subjects: 1010
Study 32316994 — intervention group
Group type: EXPERIMENTAL
Intervention: Different methods of handling urine output (UO)
Number of subjects: 1010
Study 32316994 — intervention group
Group type: EXPERIMENTAL
Intervention: All 30 variations of KDIGO criteria
Number of subjects: 1010
Study 35509395 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO) at 40 L min−1
Number of subjects: 40
Study 35509395 — intervention group
Group type: COMPARATOR
Intervention: Standard low-flow nasal cannula (NC group)
Number of subjects: 40
Study 32838710 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoids (CSN) 12 mg, single dosage
Number of subjects: 9
Study 32838710 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules with a high‐carbohydrate meal (2 g carb/kg bodyweight)
Number of subjects: 9
Study 32838710 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoids (CSN)
Number of subjects: 9
Study 35968688 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face learning
Number of subjects: 82
Study 35968688 — intervention group
Group type: COMPARATOR
Intervention: Online learning
Number of subjects: 82
Study 34599622 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AGE diet for 1 month
Number of subjects: 20
Study 34599622 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 20
Study 35836948 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-session acupuncture at true acupoints for 4 weeks
Number of subjects: 80
Study 35836948 — intervention group
Group type: COMPARATOR
Intervention: Non-penetrating sham acupuncture at non-acupoints for 4 weeks
Number of subjects: 80
Study 33256506 — intervention group
Group type: EXPERIMENTAL
Intervention: Breviscapine (BRE) 120 mg daily (40 mg, three times a day) for 14 days
Number of subjects: 18
Study 33256506 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 18
Study 33256506 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BRE and placebo groups
Number of subjects: 18
Study 33256506 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR1 C3435T gene polymorphisms (CC, CT, TT genotypes)
Number of subjects: 18
Study 34329898 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 398
Study 34329898 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 398
Study 32335402 — intervention group
Group type: EXPERIMENTAL
Intervention: Low testosterone (T) group
Number of subjects: 2118
Study 32335402 — intervention group
Group type: COMPARATOR
Intervention: Normal testosterone (T) group
Number of subjects: 2118
Study 35241032 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pelvic circumferential compression device (pelvic binder)
Number of subjects: 30
Study 35241032 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional stepwise approach)
Number of subjects: 30
Study 34581297 — intervention group
Group type: EXPERIMENTAL
Intervention: TearCare (TC)
Number of subjects: 135
Study 34581297 — intervention group
Group type: COMPARATOR
Intervention: LipiFlow (LF)
Number of subjects: 135
Study 34661682 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block with 20ml of 0.25% levobupivacaine plus dexamethasone 2mg per side
Number of subjects: 60
Study 34661682 — intervention group
Group type: COMPARATOR
Intervention: Standard multimodal analgesia with tramadol 100mg at the end of the procedure
Number of subjects: 60
Study 34053466 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive integrated vector management (IVM) strategy including targeted outdoor residual spraying with K-Othrine Polyzone, deployment of mosquito traps as auto-dissemination devices, and community engagement activities.
Number of subjects: 300
Study 34053466 — intervention group
Group type: COMPARATOR
Intervention: Routine vector control activities only.
Number of subjects: 300
Study 32759361 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-CGM/GTS
Number of subjects: 72
Study 32759361 — intervention group
Group type: COMPARATOR
Intervention: POC
Number of subjects: 72
Study 36453681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tong Guan Li Qiao needling method combined with swallowing training
Number of subjects: 116
Study 36453681 — intervention group
Group type: COMPARATOR
Intervention: Swallowing training (control group)
Number of subjects: 116
Study 32691513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 0
Study 32691513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35862407 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based couple education and counseling
Number of subjects: 288
Study 35862407 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 288
Study 34621181 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT+RT
Number of subjects: 26
Study 34621181 — intervention group
Group type: COMPARATOR
Intervention: RT+HIIT
Number of subjects: 26
Study 35251558 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention-centered targeted nursing model (group A)
Number of subjects: 120
Study 35251558 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing combined with rehabilitation intervention (group B)
Number of subjects: 120
Study 34397234 — intervention group
Group type: EXPERIMENTAL
Intervention: Thue-Morse quasiperiodic driving
Number of subjects: 0
Study 34397234 — intervention group
Group type: EXPERIMENTAL
Intervention: Random multipolar driving
Number of subjects: 0
Study 32345372 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 90